Stephane Bancel - 10 Aug 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Footnote F1

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $170.29 to $171.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $171.30 to $172.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $172.31 to $173.31. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F5

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $173.32 to $174.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F6

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $174.34 to $174.43. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F7

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $171.15 to $172.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F8

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $172.17 to $173.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F9

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $173.18 to $174.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F10

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $174.19 to $175.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F11

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $175.21 to $176.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F12

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $176.22 to $177.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F13

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $177.32 to $177.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F14

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $178.41 to $179.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F15

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $179.50 to $179.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F16

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019.

Footnote F17

These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Footnote F18

These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Footnote F19

This option is fully vested and exercisable.